Blood-based AD biomarkers often have smaller effect sizes than the corresponding CSF biomarkers (with the exception of GFAP) [25], possibly due to signal attenuation caused by counterpart proteins secreted or biomarkers sequestered by peripheral tissues and the increased biological complexity of blood [13, 30] (further discussed below). This evidence concerns the gene GFAP and Alzheimer disease.